Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06041490` - Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation	Phase 2
Not yet recruiting	`NCT05515068` - Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Completed	`NCT00093821` - Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors	Phase 1
Active, not recruiting	`NCT03233204` - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Phase 2
Completed	`NCT01553539` - Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT00091182` - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment	Phase 2
Completed	`NCT00004241` - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Phase 1
Completed	`NCT00004078` - Irinotecan in Treating Children With Refractory Solid Tumors	Phase 2
Active, not recruiting	`NCT04284774` - Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Phase 2
Recruiting	`NCT04851119` - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03213678` - Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Recruiting	`NCT04668300` - Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma	Phase 2
Completed	`NCT02470091` - Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma	Phase 2
Completed	`NCT01807052` - Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas	N/A
Completed	`NCT01016015` - Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma	Phase 2
Active, not recruiting	`NCT03698994` - Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Active, not recruiting	`NCT03213665` - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Phase 2
Not yet recruiting	`NCT03205644` - VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04320888` - Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	Phase 2
Completed	`NCT00030667` - Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood	Phase 2

NCT number	NCT02502786
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	July 2015
Completion date	July 2025

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms